Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Developing a tracking system for coagulation factor concentrates in southern Ontario.

Irwin R Walker1, Julia T Sek, Theresa M Almonte

  • 1McMaster University Medical Center, 1200 Main St. West, Hamilton, Ontario, Canada, L8N 3Z5, USA. walkeri@mcmaster.ca

Transfusion
|April 19, 2003
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical Outcomes of Efanesoctocog Alfa Prophylaxis in Children With Severe Haemophilia A: Interim Data From XTEND-ed.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same author

Enhanced antithrombogenic performance of microfluidic oxygenators through dual bioactive surface modification for an artificial placenta system.

Acta biomaterialia·2026
Same author

Individual Comparative PK Evaluation of Single-dose Octocog Alfa, Rurioctocog Alfa Pegol, and Efanesoctocog Alfa in Adults with Severe Hemophilia A.

TH open : companion journal to thrombosis and haemostasis·2026
Same author

Case Report: Atypical presentations of neonatal and infantile hemophilia B.

Frontiers in pediatrics·2026
Same author

Defining Roles in Pediatric Palliative Care: Perspectives From Oncology and Palliative Care Teams.

Pediatric blood & cancer·2026
Same author

Mim8 Bispecific Antibody Prophylaxis in Hemophilia A with or without Inhibitors.

The New England journal of medicine·2026

A new tracking system for coagulation factor concentrates was developed to improve safety and efficiency. The system successfully accounted for all products, enabling better management of resources and adverse events in hemophilia care.

Area of Science:

  • Hematology
  • Public Health
  • Health Informatics

Background:

  • Response to the AIDS epidemic prompted recommendations for improved tracking of transfusion-transmitted agents.
  • Development of a comprehensive, verifiable regional tracking system for coagulation factor concentrates was initiated.
  • Hemophilia treatment requires robust systems for managing essential blood products.

Purpose of the Study:

  • To develop and implement a verifiable and comprehensive regional tracking system for coagulation factor concentrates.
  • To monitor the distribution and utilization of factor concentrates in a specific region.
  • To enhance patient safety and resource management in hemophilia care.

Main Methods:

  • Data on distribution and utilization of factor concentrates were collected from multiple sources, including Canadian Blood Services, regional hospitals, and home-based therapy patients.

Related Experiment Videos

  • The Canadian Hemophilia Assessment and Resource Management System (CHARMS) software was employed for data storage, monitoring, analysis, and validation.
  • A 1-year period (2001) was used to track all factor concentrates distributed within the region.

    • Main Results:

    • All distributed factor concentrates within the region were accounted for during the study period.
    • A significant majority of Factor VIII (FVIII) and Factor IX (FIX) concentrates were administered at home (88%) and used for bleed prevention (63%).
    • A 5% reduction in FVIII and FIX concentrate utilization was observed during a period of shortage, and a product recall was managed efficiently. Two allergic skin reactions were reported.

    Conclusions:

    • A verifiable tracking system for coagulation factor concentrates has been successfully developed, providing valuable clinical and administrative data.
    • Future objectives include enhancing the efficiency of patient data collection and implementing real-time recording capabilities.
    • The cost-effectiveness of such a tracking system is demonstrated, estimated at less than 1.5% of the factor concentrate expenditure.